|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||749.40 - 758.00|
|52 Week Range||516.20 - 785.40|
|Beta (5Y Monthly)||0.42|
|PE Ratio (TTM)||79.28|
|Earnings Date||Jul 23, 2021|
|Forward Dividend & Yield||3.00 (0.40%)|
|Ex-Dividend Date||May 10, 2021|
|1y Target Est||762.54|
Subscribe to Yahoo Finance Plus to view Fair Value for LONN.SWLearn more
By Dhirendra Tripathi
Moderna said on Tuesday its COVID-19 vaccine manufacturing partners outside the United States are facing delays due to laboratory testing operations that have occurred in the past few days, slowing the supply of the shot to these markets. The vaccine maker's comments come after South Korean health officials said earlier in the day that Moderna has delayed its late-July vaccine shipment schedule for the country to August due to supply problems. "We are currently not reserving safety stock to allow vaccines to be delivered faster, which means that we do not have stock in storage to smooth these types of shortfalls or delays," a Moderna spokesperson said.
ZURICH (Reuters) -Swiss contract drugmaker Lonza raised its 2021 outlook on Friday after booming business making ingredients for COVID-19 vaccines and strong growth elsewhere helped it beat analysts' expectations during the first half of the year. "In the prior year we provided an estimate for how much we expected from Moderna sales for 2021...the number is much higher given our ability to increase output at our existing facilities," Chief Financial Officer Rodolfo Savitzky told reporters. Its previous guidance had been for sales growth in the low double-digit range.